Premium
Treatment and prevention of relapse of mild oesophagitis with omeprazole and cisapride: comparison of two strategies
Author(s) -
KIMMIG J. M.
Publication year - 1995
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.1995.tb00382.x
Subject(s) - cisapride , medicine , omeprazole , gastroenterology , maintenance therapy , esophagitis , surgery , chemotherapy , reflux , disease
SUMMARY Background : Oesophagitis is usually a chronic condition. Healing with omeprazole is often followed by early relapse. Combination treatment and subsequent maintenance treatment with the prokinetic cisapride may be of benefit in relapse prevention. Methods : Patients with endoscopically proven oesophagitis, grade I ( n = 120) or grade II ( n = 105), were randomized in an open fashion to receive 8 weeks of healing treatment with omeprazole 20 mg daily (OM) followed by 12 months of follow‐up without maintenance treatment, or 8 weeks of combined treatment of omeprazole 20 mg daily plus cisapride 5 mg t.d.s. (OMCIS) followed by 12 months of maintenance treatment with cisapride 5 mg t.d.s. (CIS). Only the patients healed after acute treatment were included in the 12‐month follow‐up study for evaluation of endoscopic relapse. Results : In the group of patients with oesophagitis grade I ( n = 58 receiving OM, n = 62 receiving OMCIS), healing rates were comparable for both acute treatment regimens. In the group of patients with grade II ( n = 54 receiving OM, n = 51 receiving OMCIS), the healing rates were slightly but not significantly in favour of OMCIS after 4 and 8 weeks of treatment. During the 12 months of follow‐up, CIS maintenance treatment was associated with a significant reduction of relapse. In the group of patients with initial grade I oesophagitis, the relapse rates after 3 months were 20% in the OMCIS group receiving CIS maintenance treatment, compared to 48 % in the group healed on OM without further maintenance treatment ( P = 0.04). After 6 months, these relapse rates were 31% and 85% respectively ( P < 0.001), and after 12 months 40% and 96% ( P < 0.001). In the group of patients with initial grade II oesophagitis, they were, respectively, 20% vs. 39% after 3 months ( P = 0.056), 41% vs. 78% after 6 months ( P < 0.001) and 52% vs. 95 % after 12 months ( P < 0.001). Conclusions : The results of this open study indicate that continued treatment with cisapride 5 mg t.d.s. (after initial healing with omeprazole 20 mg daily plus cisapride 5 mg t.d.s.) is beneficial in the long‐term management of grade I and II oesophagitis : this treatment approach significantly reduces the high relapse rate observed after stopping healing treatment with omeprazole.